Kings Path Partners LLC Buys 17,155 Shares of Phibro Animal Health Corporation $PAHC

Kings Path Partners LLC purchased a new position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 17,155 shares of the company’s stock, valued at approximately $613,000.

A number of other institutional investors also recently added to or reduced their stakes in PAHC. Engineers Gate Manager LP raised its stake in shares of Phibro Animal Health by 112.8% during the second quarter. Engineers Gate Manager LP now owns 52,914 shares of the company’s stock valued at $1,662,000 after purchasing an additional 28,052 shares in the last quarter. Cvfg LLC acquired a new stake in Phibro Animal Health in the first quarter worth about $2,962,000. Ranger Investment Management L.P. acquired a new stake in Phibro Animal Health in the second quarter worth about $9,182,000. Castleark Management LLC bought a new position in Phibro Animal Health in the 1st quarter valued at about $7,904,000. Finally, Advisors Preferred LLC bought a new position in Phibro Animal Health in the 1st quarter valued at about $2,931,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PAHC shares. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 18th. Weiss Ratings restated a “hold (c+)” rating on shares of Phibro Animal Health in a research report on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $47.67.

Phibro Animal Health Stock Performance

PAHC opened at $39.25 on Thursday. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of 12.09, a price-to-earnings-growth ratio of 1.12 and a beta of 0.42. The company has a debt-to-equity ratio of 1.84, a current ratio of 2.96 and a quick ratio of 1.27. Phibro Animal Health Corporation has a 1-year low of $28.25 and a 1-year high of $60.08. The business has a 50 day moving average price of $36.49 and a two-hundred day moving average price of $38.05.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, August 26th. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.14. Phibro Animal Health had a return on equity of 37.86% and a net margin of 6.57%. The firm had revenue of $396.75 million during the quarter, compared to analyst estimates of $381.18 million. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. Research analysts predict that Phibro Animal Health Corporation will post 3.49 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 23rd. Stockholders of record on Wednesday, September 2nd were issued a $0.12 dividend. The ex-dividend date was Wednesday, September 2nd. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. Phibro Animal Health’s dividend payout ratio is 19.67%.

Phibro Animal Health Profile

Phibro Animal Health Corporation develops, manufactures and sells products designed to support the health, nutrition and productivity of food-producing animals. Its offerings include animal health products, vaccines, medicated feed additives, nutritional specialties and performance products used in livestock, poultry and aquaculture.

The company’s products are intended to help prevent and manage disease, improve animal well-being and support efficient food production. Phibro serves producers, veterinarians, feed manufacturers and distributors through a portfolio that includes pharmaceuticals, vaccines, mineral and nutritional supplements, and other feed and water solutions.

Phibro Animal Health markets its products internationally across a broad range of geographic regions, including North America, Latin America, Europe, Asia-Pacific and other global markets.